Unprecedented benefit seen in test of three-drug treatment for multiple myeloma

In the treatment of multiple myeloma, the addition of carfilzomib to a currently accepted two-drug combination produced significantly better results than using the two drugs alone, according to a worldwide research team led by investigators from Mayo Clinic. Their findings will be reported online Dec. 6 in the New England Journal of Medicine , and presented on Dec. 7 at the annual meeting of the American Society of Hematology , held in San Francisco.

http://ift.tt/1q8vcNF